Evidence map›Paper›PMID 30515269›Full record

ArticleOncotarget2018

Bloodstream infection due to

Bo Tu, Jingfeng Bi, Dan Wu, Peng Zhao, Lei Shi, Yangxin Xie, Xin Zhang, Zhe Xu, Suxia Liu, Xinhua Wang and 3 more

Open access · diamondAbstract read
In one paragraph

Article in Oncotarget, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 2 pooled it
0.1field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 2 syntheses or guidelines pooled it, 10 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 1 institution in 1 country.

Bo TuCenter for Infectious Disease, Beijing 302 Hospital, Beijing 100039, China.
Jingfeng BiCenter for Clinical Research Management, Beijing 302 Hospital, Beijing 100039, China.
Dan WuCenter for Infectious Disease, Beijing 302 Hospital, Beijing 100039, China.
Peng ZhaoCenter for Infectious Disease, Beijing 302 Hospital, Beijing 100039, China.
Lei ShiCenter for Infectious Disease, Beijing 302 Hospital, Beijing 100039, China.
Yangxin XieCenter for Infectious Disease, Beijing 302 Hospital, Beijing 100039, China.
Xin ZhangCenter for Infectious Disease, Beijing 302 Hospital, Beijing 100039, China.
Zhe XuCenter for Infectious Disease, Beijing 302 Hospital, Beijing 100039, China.
Suxia LiuCenter for Liver Failure, Beijing 302 Hospital, Beijing 100039, China.
Xinhua WangCenter for Obstetrics and Gynecology, Beijing 302 Hospital, Beijing 100039, China.
Xiaoxi LiCenter for Clinical Laboratory, Beijing 302 Hospital, Beijing 100039, China.
Fusheng WangCenter for Infectious Disease, Beijing 302 Hospital, Beijing 100039, China.
Enqiang QinCenter for Infectious Disease, Beijing 302 Hospital, Beijing 100039, China.
302 Military Hospital of China · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesThe study aimed to investigate the clinical characteristics and antibiotic management, as well as independent indicators for survival within 30 days for Escherichia coli bloodstream infection (BSI) in liver cirrhosis.

resultsHospital-acquired BSI accounted for 60.07%, with prolonged hospital stay ( MATERIALS AND

methodsThe clinical data were collected from 288 eligible patients, and compared according to survival status and sites of infection acquisition. Drug resistance was recorded according to ESBL. In addition, cox regression analysis model was applied to evaluate the risk factors for 30-day mortality.

conclusionsESBL production can promote resistance to antibiotics in Escherichia coli. Antibiotic regimens, ICU admission, HE and MELD score can help identify the risk individuals who will benefit from the improved therapeutic regimens.

Indexed as

bloodstream infectionESBLhospital-acquired BSIliver cirrhosisMELD

Identifiers

PMID30515269
PMCPMC6254670
OpenAlexW2771478862

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.